RAPAMUNE 1 MG
SIROLIMUS : 1 MG · DIN 02243237 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is RAPAMUNE?
RAPAMUNE 1 MG contains SIROLIMUS : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02243237, held by PFIZER CANADA ULC, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Jun-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RAPAMUNE used for?
Prophylaxis of organ rejection in patients receiving allogeneic renal transplants. Used in regimens with cyclosporine and corticosteroids.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is RAPAMUNE called?
Also recorded in Canada as: sirolimus 100 MG Injection [Fyarro] (US), sirolimus 0.002 MG/MG Topical Gel [Hyftor] (US), sirolimus 2.4 MG Delayed Release Oral Tablet [Felycin] (US), sirolimus 1.2 MG Delayed Release Oral Tablet [Felycin] (US), sirolimus 0.4 MG Delayed Release Oral Tablet [Felycin] (US), sirolimus 1 MG/ML Oral Solution [Rapamune] (US), sirolimus 1 MG Oral Tablet [Rapamune] (US), sirolimus 2 MG Oral Tablet [Rapamune] (US), sirolimus 0.5 MG Oral Tablet [Rapamune] (US), sirolimus 100 MG Injection (US), sirolimus 0.002 MG/MG Topical Gel (US), sirolimus 2.4 MG Delayed Release Oral Tablet (US), sirolimus 1.2 MG Delayed Release Oral Tablet (US), sirolimus 0.4 MG Delayed Release Oral Tablet (US), sirolimus 1 MG/ML Oral Solution (US).
The same molecule, SIROLIMUS, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Sirolimus BOS | Latin | Saudi Arabia |
| Hyftor Gel | Latin | Iceland |
| sirolimus | Latin | Saudi Arabia |
| Siromune | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02243237 |
|---|---|
| Brand name | RAPAMUNE |
| Generic / active ingredient | SIROLIMUS : 1 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AH01 SIROLIMUS |
| AHFS class | 90:28.24.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Jun-2013 |
| Original market date | 2001-05-15 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02243237 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243237 |
| Brand name | RAPAMUNE |
| Active ingredient / INN | SIROLIMUS : 1 MG |
| ATC code | L04AH01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04 |
| AHFS class | 90:28.24.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA ULC |
How is it administered?
Initially with cyclosporine and corticosteroids. Loading dose is 3x maintenance. Low-risk: 2mg/day maintenance. High-risk: 5mg/day maintenance. Take 4 hours after cyclosporine.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned in TOC but content not in snippet). Oral solution contains ethanol.
How is it supplied?
Oral Solution: 60 mL amber glass bottles with oral syringes. Tablets: Bottles of 100; Unit dose cartons of 100 (10 x 10 blisters).
Which pack is which?
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | ORAL |
| Packaging as described in the monograph | Oral Solution: 60 mL amber glass bottles with oral syringes. Tablets: Bottles of 100; Unit dose cartons of 100 (10 x 10 blisters). |
| Storage | Not explicitly detailed in provided text (section 11 mentioned in TOC but content not in snippet). Oral solution contains ethanol. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to sirolimus, its derivatives, or any ingredient in the formulation.
Warnings and precautions
Increased risk of infection and lymphoma. Not recommended for liver or lung transplant. Risk of angioedema, hyperlipidemia, and interstitial lung disease. Monitor blood concentrations.
What can be used instead?
Other Canadian products sharing ATC code L04AH01 SIROLIMUS. 2 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RAPAMUNE | 1 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02247111 |
| GD-SIROLIMUS | 1 MG | SOLUTION | GENMED A DIVISION OF PFIZER CANADA ULC | APPROVED | DIN 02373386 |
| GD-SIROLIMUS | 1 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | APPROVED | DIN 02373394 |
| GD-SIROLIMUS | 2 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02373408 |
| GD-SIROLIMUS | 5 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02373416 |
| RAPAMUNE | 2 MG | TABLET | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02270617 |
| RAPAMUNE | 5 MG | TABLET | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02270684 |
Who else supplies SIROLIMUS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SIROLIMUS appears in 83 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does SIROLIMUS cost around the world?
SIROLIMUS is listed on 17 national price registers Nexara tracks, across 124 pack listings published on 15 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 4 | 34 | 03 Sep 2026 |
| South Africa | single exit price | 30 | 31 | 01 Sep 2026 |
| Australia | ex-manufacturer | 1 | 16 | 08 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 4 | 7 | 03 Sep 2026 |
| Iceland | max wholesale | 3 | 7 | 02 Sep 2026 |
| Saudi Arabia | public | 4 | 5 | 01 Sep 2026 |
| Spain | PVP con IVA (public price) | 4 | 4 | 05 Sep 2026 |
| Hungary | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 4 | 4 | 02 Sep 2026 |
| Czechia | max producer price (ex-factory) | 1 | 3 | 03 Sep 2026 |
| Luxembourg | reimbursement | 3 | 3 | 05 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 1 | 1 | 07 Sep 2026 |
| Romania | max producer price | 1 | 1 | 03 Sep 2026 |
| Slovakia | categorised final price | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.